

Dry Eye Disease (DED) Report

Date: 25 November 2009

"Copyright 2009 CBDMT SARL. All rights reserved. Any unauthorized use or disclosure is prohibited. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared for general circulation and is circulated for general information only. It does not have regard to specific investment objectives, financial situation and the particular needs of any particular person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussed or recommended in this report and should understand that the statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities or options or futures contracts. CBDMT SARL accepts no responsibility or liability whatsoever for any expense, loss or damages arising out of or in any way connected with the use of all or any part of this report. CBDMT SARL does not have long or short position in any securities or options of this issue(s)."

Table of Content

Presentation - Global Information.....	4
Mechanism of dry eye.....	6
The Epidemiology of Dry Eye Disease	9
Diagnostics	11
Slit-lamp Examination	12
Symptom Questionnaires	12
Grading Ocular Surface Staining	12
Tear Film Break-up Time –TFBUT.....	12
Reflex Tear Flow - Schirmer’s Test	12
Tear Osmolarity	13
Market.....	14
Eye care Market Overview	14
Dry Eye Market Overview.....	16
Treatment and Product.....	20
Tear supplementation: lubricants.....	23
Ointments.....	28
Tear Retention	28
Tear Stimulation: Secretagogues.....	32
Anti-Inflammatory Therapy	33
Cyclosporine	33
Corticosteroids.....	34
Tetracyclines	34
Surgical treatment	34
Restasis.....	35
Products in development.....	36
Prolacria (Inspire / Allergan / Santen).....	37
Clinical Data	39
Regulatory	40
Rebamipide (Ostuka/ Novartis/ Acucela).....	42
Ecabet Sodium (ISTA Pharmaceuticals).....	44

Clinical Data	45
Vekacia (Novagali Pharma).....	47
Clinical Data	47
Vismed (TRB, Jamjoom / Alcon /Lantibio).....	50
Civamide (Opko Health)	53
ST-603 (Sirion Therapeutics).....	54
ALTY-0501 (Alacrity Biosciences)	54
AL-2178 FID109980 (Alcon)	55
EGP-437 (Eyegate Pharma).....	55
Clinical Data	55
Regulatory	56
RX-10045 (Resolvix Pharmaceuticals)	57
Clinical Data	58
SAR-1118 (Sunesis Pharmaceuticals / SARcode)	59
Licensing and General info	60
Clinical Data	61

List of Figures

Figure 1: Major etiological causes of dry eye	5
Figure 2: Mechanisms of dry eye	6
Figure 3: Dry eye cascade.....	8
Figure 4: Prevalence by age and sex.....	10
Figure 5: Schematic illustration of the relationship between dry eye and other forms of ocular surface disease (OSD); MGD = Meibomian gland dysfunction	11
Figure 6: Global segment size of the ophthalmologic market in 2008 (*including lens care, OTC and contact lens)	14
Figure 7: Pharmaceuticals segment growth of the ophthalmology market (\$m)	15
Figure 8: Global leader in eye care 2006 sales (market shares).....	15
Figure 9: The six main therapeutic segments of the ophthalmology market by market share	16
Figure 10: Dry Eye market growth (\$m) for years 2006 through 2014.....	17
Figure 11: Global market for dry eye products by region (\$m)	18
Figure 12: Restasis sales in \$ million (forecasts 2009-2014)	19

List of Tables

Table 1: Summary of population-based epidemiologic studies of dry eye	9
Table 2: Practical sequence of tests.....	11
Table 3: Symptom questionnaires in current use.....	12
Table 4: Alphabetical listing of tests used to diagnose and monitor dry eye	13
Table 5: Eye care market segments	14
Table 6: Dry eye menu of treatments	21
Table 7: Treatment recommendations by dry eye severity level	22
Table 8: Low viscosity lubricants	24
Table 9: High viscosity lubricants.....	25
Table 10: Unknown viscosity lubricants.....	25
Table 11: Artificial Tear Products From Alcon, Allergan and Bausch & Lomb	26
Table 12: Lacrisert® Description - DED Prescription Ophthalmologic Drugs.....	27
Table 13: Hypertonic ointments (sodium chloride 5.0%)	28
Table 14: Petrolatum/Mineral oil ointments	28
Table 15: Silicone punctal plugs	29
Table 16: Silicone Intracanalicular Plugs	29
Table 17: Silicone Intracanalicular Plugs	30
Table 18: Moisture Chamber Spectacles.....	31
Table 19: Restasis® Description - DED Prescription Ophthalmologic Drugs	33
Table 20: List of products in development.....	36
Table 21: Prolacria (Diquafosol tetrasodium)	41
Table 22: Rebamipide Last Clinical Trials	43
Table 23: Ecabet Last Clinical Trials	46
Table 24: Vekacia Last Clinical Trials.....	50
Table 25: ST-603 Last Clinical Trials	54
Table 26: ALTY-0501 Last Clinical Trial.....	54
Table 27: AL-2178 FID109980 Last Clinical Trial	55
Table 28: EGP-437 Last Clinical Trial	57
Table 29: RX-10045 Last Clinical Trial	59
Table 30: SAR-1118 Last Clinical Trial	61